Research Topics
| D S PearlmanSummaryAffiliation: Colorado Allergy and Asthma Centers Country: USA Publications
| Collaborators
|
Detail Information
Publications
Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthmaSandra D Anderson
Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia
Respir Res 10:4. 2009....- Reproducibility of the airway response to an exercise protocol standardized for intensity, duration, and inspired air conditions, in subjects with symptoms suggestive of asthmaSandra D Anderson
Department of Respiratory and Sleep Medicine, 11 West, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia
Respir Res 11:120. 2010..This study examined reproducibility of % fall in FEV1 and area under the FEV1 time curve for 30 minutes in response to two exercise tests performed with the same intensity and duration of exercise, and inspired air conditions... - Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthmaJoseph M Parker
MedImmune LLC, Gaithersburg, MD, USA
BMC Pulm Med 11:14. 2011..Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody, in asthmatics... 
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthmaDavid S Pearlman
Colorado Allergy and Asthma Centers PC, Denver, USA
Ann Allergy Asthma Immunol 101:90-5. 2008..Indacaterol is a novel once-daily inhaled beta2-agonist in development for the treatment of patients with asthma or chronic obstructive pulmonary disease...- An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasmD S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, USA
J Asthma 44:729-33. 2007..Objective. This study evaluated the ability of levalbuterol hydrofluoroalkane (HFA) 90 mug (two actuations of 45 microg) administered via metered dose inhaler (MDI) to protect against EIB in mild-to-moderate asthmatics... 
Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukastDavid S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, USA
Ann Allergy Asthma Immunol 97:98-104. 2006..Leukotriene modifiers have been shown to protect against exercise-induced bronchoconstriction (EIB) with repeated, chronic dosing...- Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthmaDavid S Pearlman
Colorado Allergy and Asthma Centers, P C, Denver, Colorado 80230, USA
J Asthma 41:797-806. 2004..g., bronchoconstriction), with FSC results in greater overall improvements in asthma control compared with treatment of either individual component alone... - Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthmaDavid S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver 80230, USA
Ann Allergy Asthma Immunol 88:227-35. 2002..Asthma is a chronic disease characterized by inflammation and bronchoconstriction. Medications that are able to effectively treat both components are advantageous... - Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitisDavid S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, USA
Ann Allergy Asthma Immunol 91:258-62. 2003..To determine whether azelastine nasal spray suppresses the dermal response to epicutaneous histamine in allergic patients and the duration of suppression after azelastine use is discontinued... - Preclinical properties of budesonide: translation to the clinical settingDavid S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, USA
Clin Ther 25:C75-91. 2003..Each of the currently available ICSs has distinct physical and pharmacokinetic properties and is delivered via different devices... - Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthmaDavid S Pearlman
Colorado Allergy and Asthma Centers, PC, Denver 80230, USA
J Allergy Clin Immunol 116:1206-12. 2005..Inhaled corticosteroids are recommended as first-line therapy for persistent asthma... - Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in childrenDavid S Pearlman
University of Colorado Health Sciences Center, Denver, Colorado, USA
Curr Med Res Opin 18:445-55. 2002..These features may be especially valuable in a young patient population... - Effectiveness and tolerability of zafirlukast for the treatment of asthma in childrenD S Pearlman
Clinical Research Centers of Colorado, PC, Aurora 80012, USA
Clin Ther 22:732-47. 2000..This study was undertaken to examine the dose-response relationship of zafirlukast (5 to 40 mg BID) and to assess the efficacy and tolerability of the 10-mg BID dose in school-aged children with mild to moderate asthma... - Evaluation of efficacy and safety of budesonide delivered via two dry powder inhalersEdward M Kerwin
Clinical Research Institute of Southern Oregon, Medford, OR 97504, USA
Curr Med Res Opin 24:1497-510. 2008..The dry powder inhaler (DPI) device for budesonide inhalation powder 200 microg (DPI-A) was redesigned to improve dosing consistency and provide new features (budesonide inhalation powder 90 microg and 180 microg; DPI-B)... - The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthmaWilliam W Busse
Department of Medicine, University of Wisconsin School of Medicine and Public Health, J5 219 CSC, Box 2454, 600 Highland Ave, Madison, WI 53792, USA
J Allergy Clin Immunol 121:1167-74. 2008.... - Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstrictionGeorge Philip
Merck Research Laboratories, Respiratory and Allergy Department, Mail code RY34B 348, 126 East Lincoln Ave, Rahway, NJ 07065, USA
Chest 132:875-83. 2007..The present objective was to assess the onset and duration of this protective action in a trial that included both positive and negative controls... - Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukastGeorge Philip
Merck Research Laboratories Rahway, NJ 07065, USA
J Asthma 44:213-7. 2007..At this timepoint, more patients taking montelukast (45/54) than taking placebo (37/54) were protected against EIB (p = 0.039). We concluded that montelukast provided significant protection against EIB at 2 hours after a single dose... - Variability of symptoms in mild persistent asthma: baseline data from the MIAMI studyRobert S Zeiger
Department of Allergy Immunology, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Boulevard, San Diego, CA 92111, USA
Respir Med 98:898-905. 2004..To describe the variability of the asthma phenotype in patients with mild persistent asthma enrolled in the Mild Asthma Montelukast versus Inhaled Corticosteroid (MIAMI) study... - Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroidsWilliam R Lumry
AARA Research Center, Dallas, TX 75231, USA
Ann Allergy Asthma Immunol 96:51-9. 2006..Therefore, some metered-dose inhaler products are being reformulated with "ozone-friendly" hydrofluoroalkane propellants... - Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trialRobert S Zeiger
Department of Allergy Immunology, Kaiser Permanente Medical Center, Los Angeles, California, USA
Am J Med 118:649-57. 2005..To determine whether montelukast is as effective as fluticasone in controlling mild persistent asthma as determined by rescue-free days... - Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitisWilliam E Berger
Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691, USA
Allergy Asthma Proc 27:214-23. 2006..All treatments were well tolerated. Desloratadine, 5 mg, and fexofenadine, 180 mg, provide comparable efficacy and tolerability in the treatment of SAR. Both treatments are significantly more effective than placebo... - Primum non nocere and "black box" warningsDavid S Pearlman
J Allergy Clin Immunol 117:30-1. 2006